Alx Oncology Holdings (ALXO) Receivables - Accured (2022 - 2024)
Alx Oncology Holdings (ALXO) posted Receivables - Accured of $5.0 million for Q2 2024, up 2647.25% sequentially from $182000.0 in Q1 2023.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Receivables - Accured (2022 - 2024) Analysis & Trends
Alx Oncology Holdings has reported Receivables - Accured for 3 years, with the latest figure at $5.0 million in Q2 2024.
- Quarterly Receivables - Accured changed N/A year-over-year to $5.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.0 million (changed N/A YoY) and the FY2022 annual result came in at $78000.0, changed N/A from the prior year.
- Receivables - Accured improved to $5.0 million in Q2 2024 per ALXO's latest filing, from $182000.0 in the prior quarter.
- Over five years, Receivables - Accured peaked at $5.0 million in Q2 2024 and troughed at $48000.0 in Q3 2022.
- A 3-year average of $1.3 million and a median of $130000.0 in 2022 frame the typical range for Receivables - Accured.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2023 | 182,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 48,000.00 |